Literature DB >> 26652902

Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK.

Lindsey S Treviño1, Michael J Bolt1, Sandra L Grimm1, Dean P Edwards1, Michael A Mancini1, Nancy L Weigel1.   

Abstract

Progesterone receptor (PR) function is altered by cell signaling, but the mechanisms of kinase-specific regulation are not well defined. To examine the role of cell signaling in the regulation of PR transcriptional activity, we have utilized a previously developed mammalian-based estrogen-response element promoter array cell model and automated cell imaging and analysis platform to visualize and quantify effects of specific kinases on different mechanistic steps of PR-mediated target gene activation. For these studies, we generated stable estrogen-response element array cell lines expressing inducible chimeric PR that contains a swap of the estrogen receptor-α DNA-binding domain for the DNA-binding domain of PR. We have focused on 2 kinases important for steroid receptor activity: cyclin-dependent kinase 2 and DNA-dependent protein kinase. Treatment with either a Cdk1/2 inhibitor (NU6102) or a DNA-dependent protein kinase inhibitor (NU7441) decreased hormone-mediated chromatin decondensation and transcriptional activity. Further, we observed a quantitative reduction in the hormone-mediated recruitment of select coregulator proteins with NU6102 that is not observed with NU7441. In parallel, we determined the effect of kinase inhibition on hormone-mediated induction of primary and mature transcripts of endogenous genes in T47D breast cancer cells. Treatment with NU6102 was much more effective than NU7441, in inhibiting induction of PR target genes that exhibit a rapid increase in primary transcript expression in response to hormone. Taken together, these results indicate that the 2 kinases regulate PR transcriptional activity by distinct mechanisms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26652902      PMCID: PMC4792227          DOI: 10.1210/me.2015-1144

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  49 in total

1.  Repression of the alpha-fetoprotein gene promoter by progesterone and chimeric receptors in the presence of hormones and antihormones.

Authors:  B Turcotte; M E Meyer; M T Bocquel; L Bélanger; P Chambon
Journal:  Mol Cell Biol       Date:  1990-09       Impact factor: 4.272

2.  Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo.

Authors:  Y Zhang; C A Beck; A Poletti; J P Clement; P Prendergast; T T Yip; T W Hutchens; D P Edwards; N L Weigel
Journal:  Mol Endocrinol       Date:  1997-06

3.  Ligand and DNA-dependent phosphorylation of human progesterone receptor in vitro.

Authors:  M K Bagchi; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

4.  Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294.

Authors:  T Shen; K B Horwitz; C A Lange
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

5.  Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites.

Authors:  T A Knotts; R S Orkiszewski; R G Cook; D P Edwards; N L Weigel
Journal:  J Biol Chem       Date:  2000-12-07       Impact factor: 5.157

6.  The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation.

Authors:  E K Gass; S A Leonhardt; S K Nordeen; D P Edwards
Journal:  Endocrinology       Date:  1998-04       Impact factor: 4.736

7.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

8.  Breast cancer and hormone-replacement therapy in the Million Women Study.

Authors:  Valerie Beral
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

9.  Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II.

Authors:  Y Zhang; C A Beck; A Poletti; D P Edwards; N L Weigel
Journal:  J Biol Chem       Date:  1994-12-09       Impact factor: 5.157

10.  Progesterone receptor and the mechanism of action of progesterone antagonists.

Authors:  D P Edwards; M Altmann; A DeMarzo; Y Zhang; N L Weigel; C A Beck
Journal:  J Steroid Biochem Mol Biol       Date:  1995-06       Impact factor: 4.292

View more
  6 in total

1.  Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.

Authors:  Emanuela Dylgjeri; Christopher McNair; Jonathan F Goodwin; Heather K Raymon; Peter A McCue; Ayesha A Shafi; Benjamin E Leiby; Renée de Leeuw; Vishal Kothari; Jennifer J McCann; Amy C Mandigo; Saswati N Chand; Matthew J Schiewer; Lucas J Brand; Irina Vasilevskaya; Nicolas Gordon; Talya S Laufer; Leonard G Gomella; Costas D Lallas; Edouard J Trabulsi; Felix Y Feng; Ellen H Filvaroff; Kristin Hege; Dana Rathkopf; Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2019-07-02       Impact factor: 12.531

Review 2.  Targeted and systemic insights into the crosstalk between DNA-dependent protein kinase catalytic subunit and receptors of estrogen, progesterone and epidermal growth factor in the context of cancer.

Authors:  Soubiya Mohammed Rizwan Ansari; Farah Saleh Hijazi; Serhiy Souchelnytskyi
Journal:  Mol Biol Rep       Date:  2021-11-03       Impact factor: 2.316

3.  Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.

Authors:  Suriyan Ponnusamy; Christopher C Coss; Thirumagal Thiyagarajan; Kate Watts; Dong-Jin Hwang; Yali He; Luke A Selth; Iain J McEwan; Charles B Duke; Jayaprakash Pagadala; Geetika Singh; Robert W Wake; Christopher Ledbetter; Wayne D Tilley; Tudor Moldoveanu; James T Dalton; Duane D Miller; Ramesh Narayanan
Journal:  Cancer Res       Date:  2017-10-04       Impact factor: 12.701

4.  Leveraging Image-Derived Phenotypic Measurements for Drug-Target Interaction Predictions.

Authors:  Srikanth Kuthuru; Adam T Szafran; Fabio Stossi; Michael A Mancini; Arvind Rao
Journal:  Cancer Inform       Date:  2019-06-12

5.  Global signalling network analysis of luminal T47D breast cancer cells in response to progesterone.

Authors:  Roni H G Wright; Viviana Vastolo; Javier Quilez Oliete; José Carbonell-Caballero; Miguel Beato
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-11       Impact factor: 6.055

6.  A Mechanistic High-Content Analysis Assay Using a Chimeric Androgen Receptor That Rapidly Characterizes Androgenic Chemicals.

Authors:  Adam T Szafran; Michael J Bolt; Caroline E Obkirchner; Maureen G Mancini; Christine Helsen; Frank Claessens; Fabio Stossi; Michael A Mancini
Journal:  SLAS Discov       Date:  2020-05-11       Impact factor: 3.341

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.